Sunday 22 Nov 2026
main news image

This article first appeared in The Edge Malaysia Weekly on August 18, 2025 - August 24, 2025

Kotra Industries

Melaka-based pharmaceutical group Kotra Industries Bhd (KL:KOTRA) once again received significant recognition at The Edge Malaysia Centurion Club Corporate Awards 2025, securing double wins under the healthcare sector. This year, however, marked the end of Kotra’s remarkable four-year streak of sweeping all three awards in its category.

A dominant force since the inaugural awards in 2019,  Kotra has been taking home awards for Highest Return On Equity (ROE) Over Three Years, Highest Growth In Profit After Tax (PAT) Over Three Years and Highest Returns To Shareholders Over Three Years in 2019, 2022, 2023 and 2024.

In 2023, it was also named Centurion of The Year — an honour recognising it as the top performer among Bursa Malaysia-listed companies with a market capitalisation below RM1 billion. The awards took a two-year break in 2020 and 2021 because of the Covid-19 pandemic, resuming in 2022 as the world transitioned to a post-pandemic environment.

This year, the group again secured the PAT growth award with a three-year compound annual growth rate (CAGR) of 17.8%, according to awards methodology. This was based on its net profit, which more than doubled from RM24.4 million in FY2021 to RM62.1 million in FY2022, then climbed further to RM65.2 million in FY2023, before retreating to RM44.6 million in FY2024.

With an investment of RM210 million, Kotra developed its state-of-the-art manufacturing facility Kotra Pharma Technology Centre (KPTC) in Melaka, which was fully operational by 2013

It also took home the returns to shareholders award again, as its share price (adjusted) outperformed peers in the same category. The stock jumped from RM3.70 at end-March 2022 to RM4.95 at end-March 2023, before easing to RM4.40 a year later and subsequently to RM4.19 by March 28 this year. This gave the group a shareholder returns’ CAGR of 4.21%.

But a dip in ROE, partly attributed to the earnings drop in its latest financial year ended June 30, 2024 (FY2024), saw Kotra ceding ground in the ROE category.

The group’s ROE slipped from 27.56% in FY2022 to 25.32% in FY2023, and further to 16.3% in FY2024, resulting in a weighted average ROE of 21.3% over the three years. 

The drop in Kotra’s latest FY2024 earnings was mainly due to lower revenue from reduced sales of supplement products in both export and local markets. The group attributed the decline to the tapering off of heightened demand for pharmaceutical products, which surged in the preceding financial year, owing to global health conditions and economic reopening.

As demand returned to normalcy, revenue for the year adjusted accordingly, as stated in its latest annual report. For FY2024, pharmaceutical product sales contributed 55% of the group’s revenue, with the remaining 45% from over-the-counter (OTC) products.

Moreover, Kotra’s net margin was affected by higher tax expenses due to the reversal of deferred tax assets from the utilisation of tax losses and incentives, as well as the recognition of deferred tax liabilities.

Kotra will continue enhancing brand visibility through targeted marketing campaigns via social media and outdoor advertising.

“We will pursue new business opportunities within our existing key markets and explore new geographical areas to grow our customer base,” said the group’s managing director Piong Teck Onn in the annual report.

Kotra has been engaged in developing, manufacturing and supplying pharmaceutical and healthcare products since its inception in 1982. The group offers a wide range of OTC supplements, nutritional and pharmaceutical products in various dosage forms.

Kotra has three main brands: Appeton, Axcel and Vaxcel. Appeton offers OTC products catering forall stages of life, from prenatal development to geriatric health supplements; Axcel specialises in paediatric care, anti-infective medicine and dermatological care; and Vaxcel products focus on sterile injectables featuring a range of antibiotics to treat extensive health conditions.

As at end-June last year, Kotra had 62 OTC products and 146 pharmaceutical products registered in Malaysia and the international markets in which it operates.

Kotra was founded by Teck Onn’s father, the late Piong Nam Kim @ Piong Pak Kim. The Piong family controls 60% of the group.

Interestingly, former Nanyang Siang Pau business editor and prominent investor Fong SiLing — better known as Cold Eye — also owns 1.2 million shares, or a 0.81% stake, in Kotra.

Save by subscribing to us for your print and/or digital copy.

P/S: The Edge is also available on Apple's App Store and Android's Google Play.

      Print
      Text Size
      Share